FindTrial
Sign In

Accelerated Hypofractionated Radiation Therapy

RADIATION2 trials

Sponsors

National Cancer Institute (NCI), Mayo Clinic

Conditions

GlioblastomaLocally Advanced Lung Non-Small Cell CarcinomaLocally Recurrent Lung Non-Small Cell CarcinomaStage II Lung Cancer AJCC v8Stage III Lung Cancer AJCC v8Unresectable Lung Non-Small Cell Carcinoma

Phase 1

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial
CompletedNCT03801902
National Cancer Institute (NCI)Locally Advanced Lung Non-Small Cell Carcinoma, Locally Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 +2
Start: 2019-10-28End: 2025-09-04Updated: 2025-09-23

Phase 2

Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study
Active, not recruitingNCT05781321
Mayo ClinicGlioblastoma
Start: 2023-03-23End: 2028-07-02Target: 170Updated: 2026-02-03

Related Papers

Short-course hypofractionated proton beam therapy, incorporating <sup>18</sup>F-DOPA PET and contrast-enhanced MRI targeting, for patients aged 65 years and older with newly diagnosed glioblastoma: a single-arm phase 2 trial.
2024-11-188 citations
Safety results of NRG-LU004: Phase I trial of accelerated or conventionally fractionated radiotherapy combined with durvalumab in PD-L1–high locally advanced non-small cell lung cancer.
Journal of Clinical Oncology2022-06-0116 citations